SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totaling 1,344 shares, an increase of 78.0% from the September 30th total of 755 shares. Based on an average trading volume of 53,601 shares, the short-interest ratio is currently 0.0 days.
SAB Biotherapeutics Price Performance
Shares of SABSW remained flat at $0.00 during trading hours on Tuesday. SAB Biotherapeutics has a 1 year low of $0.00 and a 1 year high of $0.20. The business’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.02.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a biotechnology company focused on developing antibody-based medicines for infectious diseases, autoimmune conditions and other immune-mediated disorders. The company’s lead programs have included SAB-142, an investigational therapy for immune-mediated disease, and SAB-176, an antibody product candidate designed to address influenza A infections. SAB also developed SAB-185 for the treatment of COVID-19.
The company uses its DiversitAb platform, which involves genetically engineered cattle capable of producing fully human polyclonal antibodies.
Further Reading
- Five stocks we like better than SAB Biotherapeutics
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
